Renishaw RA802 Pharmaceutical Analyzer

Overview

The Renishaw RA802 Pharmaceutical Analyzer is a benchtop confocal micro-Raman imaging system engineered specifically for regulatory-compliant chemical and spatial characterization of pharmaceutical dosage forms. It employs spontaneous Raman scattering—based on inelastic photon-phonon interactions—to deliver label-free, molecular-specific identification without sample labeling or destruction. Unlike conventional FTIR or NIR methods, Raman spectroscopy provides high chemical specificity for active pharmaceutical ingredients (APIs), polymorphs, excipients, and coating materials—even through transparent polymer films. The RA802 integrates Renishaw’s proprietary StreamLine™ Rapid acquisition technology with LiveTrack™ real-time focus tracking, enabling robust, high-fidelity spectral mapping across topographically complex surfaces such as intact tablets, fractured cross-sections, granules, powders, and aerosol deposits. Its optical architecture conforms to ISO 17025-aligned measurement traceability principles, supporting method validation under ICH Q5A, Q5C, and USP guidelines.

Key Features

• Confocal micro-Raman imaging with <2 cm⁻¹ spectral resolution and ~500 nm lateral spatial resolution at 785 nm excitation
• LiveTrack™ autofocus system maintaining diffraction-limited focus across curved, rough, or uneven tablet surfaces during full-area raster scanning
• StreamLine™ Rapide acquisition mode delivering up to 950 spectra per second with minimal laser power density—preserving thermally sensitive APIs and coatings
• No sample preparation required: direct analysis of intact tablets, split tablets, powders, granules, liquids, and spray-dried dispersions
• Integrated performance qualification (PQ) routines compliant with ASTM E1840 and ISO/IEC 17025 calibration verification requirements
• Dual-mode operation: macro-scale survey imaging followed by targeted high-resolution chemical mapping

Sample Compatibility & Compliance

The RA802 accommodates a broad range of pharmaceutical physical forms—including coated/uncoated tablets, bi-layer formulations, lyophilized cakes, inhalation powders, transdermal patches, and suspension droplets—without physical alteration. Its non-contact, non-destructive nature ensures sample integrity for subsequent orthogonal testing (e.g., HPLC, DSC, or SEM-EDS). All hardware and software components meet CE marking requirements and are designed to support 21 CFR Part 11-compliant workflows when deployed with Renishaw’s WiRE™ 5.5 software suite configured for audit-trail-enabled environments. Data files comply with ASTM E2534 metadata standards for spectral data exchange, facilitating integration into LIMS and electronic lab notebook (ELN) systems used in GMP manufacturing and QC laboratories.

Software & Data Management

WiRE™ 5.5 software provides a structured, workflow-driven interface optimized for pharmaceutical analysts—regardless of spectroscopy background. It features automated macro-image generation for sample array overview, region-of-interest (ROI) definition tools, and batch-queue scheduling for unattended multi-sample analysis. Chemometric analysis includes hierarchical cluster analysis (HCA), principal component analysis (PCA), and Renishaw’s proprietary Empty Model™ algorithm for unsupervised component identification in unknown formulations. Spectral libraries include >1200 validated pharmaceutical reference spectra (APIs, polymorphs, common excipients) aligned with USP-NF monographs and Ph. Eur. standards. All processing steps—including baseline correction, cosmic ray removal, and multivariate modeling—are fully logged with time-stamped, user-attributed audit trails satisfying GLP/GMP documentation requirements.

Applications

• API distribution homogeneity assessment in solid dosage forms per USP
• Coating thickness uniformity and defect detection in film-coated tablets
• Polymorphic form identification and quantification in crystalline APIs
• Excipient–API interaction screening in accelerated stability studies
• Content uniformity verification in low-dose formulations (e.g., <1 mg/tablet)
• 3D chemical–topographic correlation mapping of tablet surface erosion during dissolution testing
• Forensic investigation of counterfeit medicines via spectral fingerprint matching

FAQ

Does the RA802 require routine wavelength calibration using external standards?
No. The system incorporates an internal neon calibration source and automated daily PQ checks that verify spectral accuracy to ≤±0.1 cm⁻¹ against NIST-traceable references.

Can the RA802 analyze samples through blister packaging or glass vials?
Yes—provided the packaging material exhibits low fluorescence and sufficient Raman transparency. Standard 785 nm excitation enables analysis through polypropylene blisters and borosilicate glass vials with minimal spectral interference.

Is method transfer between RA802 instruments supported?
Yes. WiRE™ software supports instrument-independent spectral processing via standardized .wdf file format and embedded acquisition metadata, ensuring consistent results across multiple RA802 units in multi-site manufacturing networks.

How does LiveTrack™ handle highly reflective or absorbing tablet surfaces?
LiveTrack™ uses dynamic signal-based focus feedback—not intensity-based contrast—enabling stable tracking on metallic-coated tablets, carbon-black–containing formulations, and highly scattering placebo matrices.

What validation documentation is supplied with the RA802 for regulated environments?
Renishaw provides IQ/OQ documentation templates, PQ protocols aligned with ASTM E2534 and ISO 17025, and a comprehensive instrument-specific Certificate of Conformance including factory spectral performance verification data.